Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)

Saved in:
Bibliographic Details
Published inMetabolism, clinical and experimental Vol. 142; p. 155455
Main Authors Alkhouri, Naim, Loomba, Rohit, Frias, Juan P., Feng, Shibao, Tseng, Leo, Agollah, Germaine D., Mansbach, Hank, Margalit, Maya, Hartsfield, Cynthia L., Harrison, Stephen
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.05.2023
Online AccessGet full text

Cover

More Information
ISSN:0026-0495
DOI:10.1016/j.metabol.2023.155455